Arcturus Therapeutics Holdings Inc. (ARCT)

24,83 -1,44 (-5,46%) A partir del 02:42PM EDT. Mercado abierto.

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 180

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Joseph E. Payne M.Sc.	Founder, President, CEO & Director	906,5k	N/A	1972
Dr. Padmanabh Chivukula Ph.D.	Founder, Chief Scientific Officer, COO & Secretary	687,5k	N/A	1979
Mr. Andrew H. Sassine MBA	CFO & Director	687,5k	N/A	1964
Mr. Lance Kurata	Chief Legal Officer	600k	N/A	N/A
Ms. Neda Safarzadeh	Vice President and Head of IR/PR & Marketing	N/A	N/A	N/A
Ms. Natash O. Bowman	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Kevin T. Skol	Chief Business Officer	N/A	N/A	N/A
Dr. Juergen Froehlich FCPh, M.D., MBA	Chief Medical Officer	N/A	N/A	1956
Dr. Igor Smolenov M.D., Ph.D.	Chief Development Officer	N/A	N/A	N/A
Ms. Roberta Duncan	Chief Strategy Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Arcturus Therapeutics Holdings Inc., a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 10; Tablero: 3; Derechos de los accionistas: 6; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.